Rutgers Cancer Institute is a clinical research site located in New Brunswick, New Jersey, United States 08901.
Crixeo Clinical Trials Trust Score: 27/100 (FAILING). This profile has not yet been claimed by the site owner.
Rutgers Cancer Institute has participated in 50 clinical trials with 42 currently active.
Therapeutic areas: Gastrointestinal Stromal Tumors, HER2 Mutation-Related Tumors, HER2.
Sponsors: Deciphera Pharmaceuticals, LLC, Iambic Therapeutics, Inc, Diakonos Oncology Corporation.
Is this your site? Claim your profile and control the information sponsors and patients see.
Browse all research sites in New Jersey · View every site in New Brunswick
Trust Score: 27/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Rutgers Cancer Institute has a Crixeo Trust Score of 27/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Rutgers Cancer Institute has 50 clinical trials on record, with 42 currently active. Their work covers Gastrointestinal Stromal Tumors, HER2 Mutation-Related Tumors, HER2.
Rutgers Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.